Overview

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

Status:
Recruiting
Trial end date:
2022-02-16
Target enrollment:
Participant gender:
Summary
This is an inpatient treatment, double-blind, randomized, 3-way crossover study in T1DM subjects using insulin pump therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Youngene Therapeutics Inc., Ltd.
Collaborator:
ProSciento
Treatments:
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
Dapagliflozin